Literature DB >> 2030355

Carcinomatous meningitis: antibody-guided therapy with I-131 HMFG1.

R P Moseley1, J C Benjamin, R D Ashpole, N M Sullivan, J A Bullimore, H B Coakham, J T Kemshead.   

Abstract

Seven patients with carcinomatous meningitis were administered intrathecal I-131 labelled monoclonal antibody HMFG1. Clinical responses were seen in two patients, with a long term survivor at 32 months. Aseptic meningitis occurred in 4/7 patients, but more serious toxicity was observed in the form of seizures (2/7 patients) and myelosuppression (3/7 patients). Partial obliteration of the subarachnoid space was identified as a potential problem in patients with advanced disease.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2030355      PMCID： PMC1014397          DOI： 10.1136/jnnp.54.3.260

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  47 in total

1.  Cerebral distribution of immunoconjugate after treatment for neoplastic meningitis using an intrathecal radiolabeled monoclonal antibody.

Authors:  J C Benjamin; T Moss; R P Moseley; R Maxwell; H B Coakham
Journal:  Neurosurgery       Date:  1989-08       Impact factor: 4.654

2.  Intrathecal arabinosyl cytosine in meningeal leukemia.

Authors:  J J Wang; C B Pratt
Journal:  Cancer       Date:  1970-03       Impact factor: 6.860

3.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess.

Authors:  T Lindmo; E Boven; F Cuttitta; J Fedorko; P A Bunn
Journal:  J Immunol Methods       Date:  1984-08-03       Impact factor: 2.303

Review 4.  Immunotoxins: hybrid molecules combining high specificity and potent cytotoxicity.

Authors:  F K Jansen; H E Blythman; D Carrière; P Casellas; O Gros; P Gros; J C Laurent; F Paolucci; B Pau; P Poncelet; G Richer; H Vidal; G A Voisin
Journal:  Immunol Rev       Date:  1982       Impact factor: 12.988

5.  In vivo localisation of radiolabelled monoclonal antibody in human gliomas.

Authors:  J Behnke; J P Mach; F Buchegger; S Carrel; B Delaloye; N De Tribolet
Journal:  Br J Neurosurg       Date:  1988       Impact factor: 1.596

6.  Leptomeningeal carcinomatosis in small cell carcinoma of the lung.

Authors:  J Aisner; S Ostrow; S Govindan; P H Wiernik
Journal:  Med Pediatr Oncol       Date:  1981

7.  Therapeutic application of a radiolabelled monoclonal antibody in nude mice xenografted with human neuroblastoma: tumoricidal effects and distribution studies.

Authors:  D H Jones; A Goldman; I Gordon; J Pritchard; B J Gregory; J T Kemshead
Journal:  Int J Cancer       Date:  1985-06-15       Impact factor: 7.396

8.  An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.

Authors:  P E Thorpe; A N Brown; J A Bremner; B M Foxwell; F Stirpe
Journal:  J Natl Cancer Inst       Date:  1985-07       Impact factor: 13.506

9.  Therapeutic irradiation of the central nervous system using intrathecal 90Y--DTA.

Authors:  S Smith; R M Thomas; H A Steere; H E Beatty; K B Dawson; M J Peckham
Journal:  Br J Radiol       Date:  1976-02       Impact factor: 3.039

10.  Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6.

Authors:  Y Lee; D E Bullard; P A Humphrey; E V Colapinto; H S Friedman; M R Zalutsky; R E Coleman; D D Bigner
Journal:  Cancer Res       Date:  1988-05-15       Impact factor: 12.701
View more
  8 in total

Review 1.  Leptomeningeal metastases from solid malignancy: a review.

Authors:  Sophie Taillibert; Florence Laigle-Donadey; Catherine Chodkiewicz; Marc Sanson; Khê Hoang-Xuan; Jean-Yves Delattre
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

2.  (124)I-huA33 antibody PET of colorectal cancer.

Authors:  Jorge A Carrasquillo; Neeta Pandit-Taskar; Joseph A O'Donoghue; John L Humm; Pat Zanzonico; Peter M Smith-Jones; Chaitanya R Divgi; Daniel A Pryma; Shutian Ruan; Nancy E Kemeny; Yuman Fong; Douglas Wong; Jaspreet S Jaggi; David A Scheinberg; Mithat Gonen; Katherine S Panageas; Gerd Ritter; Achim A Jungbluth; Lloyd J Old; Steven M Larson
Journal:  J Nucl Med       Date:  2011-07-15       Impact factor: 10.057

Review 3.  Applications of monoclonal antibodies in the investigation, diagnosis, and treatment of retinoblastoma.

Authors:  J F Tarlton; D L Easty
Journal:  Br J Ophthalmol       Date:  1993-12       Impact factor: 4.638

Review 4.  New aspects of immunotherapy of leptomeningeal metastasis.

Authors:  U Herrlinger; M Weller; M Schabet
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130

5.  Treatment of neoplastic meningitis by targeted radiation using (131)I-radiolabelled monoclonal antibodies. Results of responses and long term follow-up in 40 patients.

Authors:  H B Coakham; J T Kemshead
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130

6.  Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab.

Authors:  Abraham Boskovitz; Roger E McLendon; Tatsunori Okamura; John H Sampson; Darell D Bigner; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2009-08       Impact factor: 2.408

7.  Carcinomatous meningitis: Leptomeningeal metastases in solid tumors.

Authors:  Emilie Le Rhun; Sophie Taillibert; Marc C Chamberlain
Journal:  Surg Neurol Int       Date:  2013-05-02

Review 8.  Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer.

Authors:  Ana Turkaj; Anna M Morelli; Tiziana Vavalà; Silvia Novello
Journal:  Front Oncol       Date:  2018-07-27       Impact factor: 6.244
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.